Full Paper

An Anti-angiogenic Reverse Thermal Gel as a Drug-Delivery System for Age-Related Wet Macular Degeneration

  1. Daewon Park1,
  2. Veeral Shah2,
  3. Britta M. Rauck3,
  4. Thomas R. Friberg2,
  5. Yadong Wang3,*

Article first published online: 11 JAN 2013

DOI: 10.1002/mabi.201200384

Issue

Macromolecular Bioscience

Macromolecular Bioscience

Volume 13, Issue 4, pages 464–469, April 2013

Additional Information

How to Cite

Park, D., Shah, V., Rauck, B. M., Friberg, T. R. and Wang, Y. (2013), An Anti-angiogenic Reverse Thermal Gel as a Drug-Delivery System for Age-Related Wet Macular Degeneration. Macromol. Biosci., 13: 464–469. doi: 10.1002/mabi.201200384

Author Information

  1. 1

    Department of Bioengineering, University of Colorado Denver Anschutz Medical Campus, Aurora, Colorado 80045, USA

  2. 2

    Department of Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15219, USA

  3. 3

    Department of Bioengineering, Chemical Engineering, Surgery, McGowan Institute for Regenerative Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania 15219, USA

*Department of Bioengineering, Chemical Engineering, Surgery, McGowan Institute for Regenerative Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania 15219, USA

Publication History

  1. Issue published online: 18 APR 2013
  2. Article first published online: 11 JAN 2013
  3. Manuscript Received: 23 OCT 2012

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article with Supporting Information (HTML) Get PDF (579K)

Keywords:

  • age-related wet macular degeneration;
  • compatibility;
  • hydrogels;
  • retinal cells;
  • sustained release

Abstract

Thumbnail image of graphical abstract

Reverse thermal gels have numerous biomedical implications, as they undergo physical gelation upon temperature increases and can incorporate biomolecules to promote tissue repair. Such a material is developed for the sustained release of bevacizumab (Avastin), a drug used to treat age-related macular degeneration. The polymer, poly(ethylene glycol)-poly(serinol hexamethylene urethane) (ESHU), forms a physical gel when heated to 37 °C and shows good cytocompatibility with ocular cells. ESHU is capable of sustaining bevacizumab release over 17 weeks in vitro, and the release kinetics can be altered by changing the drug dose and the ESHU concentration. These results suggest that ESHU is biologically safe, and suitable for ocular drug delivery.

View Full Article with Supporting Information (HTML) Get PDF (579K)